A genetic variant of a receptor  in the brain’s reward circuitry heightens the stimulating effects of early  exposures to alcohol and increases alcohol consumption, according to a new study  by researchers at the National Institute on Alcohol Abuse and Alcoholism  (NIAAA), part of the National Institutes of Health (NIH).  Conducted in rhesus  monkeys, the study extends previous research that suggests an important role for  a similar brain receptor variant in the development of human alcohol use  disorders.  A report of the findings is published in the March, 2007 issue of  the Archives of General  Psychiatry.
  
 “Although the pathway to  alcoholism is influenced by many factors, our findings affirm that individuals  who possess this receptor variant may experience enhanced pleasurable effects  from alcohol that could increase their risk for developing alcohol abuse and  dependence,” notes Markus Heilig, M.D., Ph.D., NIAAA Clinical Director and the  study’s senior author.
  
 Molecules known as opioid  peptides bind to opioid receptors in the brain to signal experiences of reward  and reinforcement, as well as the euphoria and other positive subjective effects  produced by alcohol.  Previous studies have shown that, among the brain’s  various subtypes of opioid receptors, the mu-subtype is most likely responsible  for transmitting alcohol’s positive effects.
  
 “We also know that there are  several genetic variants of the human mu-opioid receptor,” notes first author  Christina Barr, V.M.D., Ph.D., a lead investigator in NIAAA’s Laboratory of  Clinical and Translational Studies and Laboratory of Neurogenetics.  “One of  these, designated 118G, has a greatly enhanced ability to bind opioid peptides.   People who have this variant of the receptor have reported increased euphoria  following alcohol consumption.”
  
 Drs. Barr, Heilig, and their  colleagues note that recent studies have linked the 118G mu-opioid receptor with  alcohol dependence in humans.  In the current study, the researchers explored  the link between genetic variants of mu-opioid receptors and alcohol-related  behaviors in a group of 82 rhesus monkeys.
  
 “A mu-opioid receptor variant  that is functionally similar to the human 118G variant occurs in these animals,”  explained Dr. Barr.  “That is, it also has a greatly enhanced ability to bind  opioid peptides.  We hypothesized that monkeys that had the gene for this  receptor variant would experience enhanced alcohol stimulation and, therefore,  consumption.
  
 Groups of monkeys had access to  both alcoholic and non-alcoholic solutions for one hour per day for a period of  six weeks.  Researchers measured the animals’ alcohol intake and post-intake  activity, and determined which monkeys carried the gene for the mu-opioid  receptor similar to the human 118G receptor.  Activity measures are commonly  used in animal studies to assess alcohol’s pleasurable effects.  As predicted,  the researchers found that monkeys with the variant gene showed increased  activity following alcohol consumption.  They also found that male animals with  the variant had a clear preference for the alcohol solution and consumed on  average almost twice as much alcohol as other animals.  Males with the variant  also became intoxicated on almost 30 percent of testing days, while other  animals did so only on an average of 8 percent of testing days.
  
 “The male-restricted effect of  this gene is interesting, and parallels other recent evidence that opioid  transmission may play a greater role in alcohol problems among some males than  among females,” explained Dr. Heilig.  This information also complements recent  data suggesting that alcohol-dependent people with the gene for the 118G  receptor have a better therapeutic response to medications that block opioid  receptors.  More broadly, the finding underscores the important role that the  pleasurable and stimulating initial effects of alcohol play in the subsequent  development of alcohol problems.”
 
  
 The  National Institute on Alcohol Abuse and Alcoholism, part of the National  Institutes of Health, is the primary U.S. agency for conducting and  supporting research on the causes, consequences, prevention, and treatment of  alcohol abuse, alcoholism, and alcohol problems and disseminates research  findings to general, professional, and academic audiences. Additional alcohol  research information and publications are available at www.niaaa.nih.gov.
 The National Institutes of Health (NIH) — The Nation's Medical Research  Agency — includes 27 Institutes and Centers and is a component of the U. S.  Department of Health and Human Services. It is the primary Federal agency for  conducting and supporting basic, clinical, and translational medical research,  and it investigates the causes, treatments, and cures for both common and rare  diseases. For more information about NIH and its programs, visit http://www.nih.gov.
 
References: Barr CS, Schwandt M, Lindell SG, Chen SA,  Goldman D, Suomi SJ, Higley, JD, Heilig M. Association of a Functional  Polymorphism in the μ-Opioid Receptor Gene With Alcohol Response and Consumption  in Male Rhesus Macaques. Archives of  General Psychiatry. 2007;64:369-376
 Ray LA, Hutchison KE. A  polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the  effects of alcohol in humans. Alcohol  Clin Exp Res. 2004;  28:1789-1795.